Obesity drug maker Novo Nordisk ousts CEO as competition weighs
Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market. Under Jorgensen’s leadership, Novo Nordisk became a world leader in the weight-loss drug market, with sky-rocketing sales of its Wegovy and Ozempic treatments which propelled … Read more